Cost-Effectiveness and Budget Impact Analysis of the Trivalent Adjuvanted Influenza Vaccine in People over 50 Years of Age for Argentina

20260 citationsJournal Articlegold Open Access

Authors

Leandro Javier Pastori · Instituto de Efectividad Clínica y Sanitaria

Constanza Silvestrini Viola · Instituto de Efectividad Clínica y Sanitaria

Tomás Alconada · Instituto de Efectividad Clínica y Sanitaria

Gonzalo Pereira · Seqirus (United States)

José Luis Montes · Olin Corporation (United States)

Joaquin Mould-Quevedo · Seqirus (United States)

Carolina Saenz

Abstract

Implementing aTIV in adults aged ≥50 with risk factors would be cost-effective and affordable in Argentina. These findings support the consolidation and potential expansion of current vaccination strategies to reduce influenza burden.

Topics & Keywords

Influenza Virus Research Studies Respiratory viral infections research Vaccine Coverage and Hesitancy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Vaccines

Volume 14, Issue 3, pp. 227-227

DOI: 10.3390/vaccines14030227

Field-Weighted Citation Impact: 0.00